Format

Send to

Choose Destination
Oncotarget. 2016 Aug 9;7(32):51619-51625. doi: 10.18632/oncotarget.10010.

Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.

Author information

1
Department of Medicine, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA.

Abstract

The consistency of in vitro drug sensitivity data is of key importance for cancer pharmacogenomics. Previous attempts to correlate drug sensitivities from the large pharmacogenomics databases, such as the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC), have produced discordant results. We developed a new drug sensitivity metric, the area under the dose response curve adjusted for the range of tested drug concentrations, which allows integration of heterogeneous drug sensitivity data from the CCLE, the GDSC, and the Cancer Therapeutics Response Portal (CTRP). We show that there is moderate to good agreement of drug sensitivity data for many targeted therapies, particularly kinase inhibitors. The results of this largest cancer cell line drug sensitivity data analysis to date are accessible through the online portal, which serves as a platform for high power pharmacogenomics analysis.

KEYWORDS:

cancer; cell line; database integration; drug sensitivity; pharmacogenomics

PMID:
27322211
PMCID:
PMC5239501
DOI:
10.18632/oncotarget.10010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center